SHR 1905
Alternative Names: AIO-001; GSK-5784283; SHR-1905Latest Information Update: 29 Jul 2026
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Atridia; GSK; Jiangsu Hengrui Medicine Co.; Shanghai Hengrui Pharmaceutical
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Asthma; Rhinosinusitis
- Phase II Atopic dermatitis
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 17 Jul 2026 GlaxoSmithKline plans a phase I trial for Asthma (In volunteers) (SC) (NCT07712393)
- 03 Dec 2025 Guangdong Hengrui Pharmaceutical completes a phase-II clinical trials in Asthma (In adolescents) in China (SC) (NCT06786455)
- 27 Nov 2025 700385174 - Updated KDM and dev line